Evidence map›Paper›PMID 34677089›Full record

ArticleJournal of managed care & specialty pharmacy2021

Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States.

Jingyan Yang, Jennifer Carioto, Bruce Pyenson, Rebecca Smith, Nathaniel Jacobson, Sean Pittinger, Ahmed Shelbaya

Open access · greenAbstract read
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Individual Prescribing Incentives for Biosimilars in Selected European Countries and the USA: a Scoping Literature Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Article
  2. Article
  3. A primer on brand-name prescription drug reimbursement in the United States.Journal of managed care & specialty pharmacy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jingyan YangPatient Health and Impact (PHI), Pfizer Inc., New York, NY, and Institute for Social and Economic Research and Policy (ISERP), Columbia University, New York, NY.
Jennifer CariotoMilliman Inc., New York, NY.
Bruce PyensonMilliman Inc., New York, NY.
Rebecca SmithMilliman Inc., New York, NY.
Nathaniel JacobsonMilliman Inc., New York, NY.
Sean PittingerMilliman Inc., New York, NY.
Ahmed ShelbayaPatient Health and Impact (PHI), Pfizer Inc., New York, NY, and Mailman School of Public Health, Columbia University, New York, NY.
Milliman (United States) · USInstitute for Social and Economic Research · GBPfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Medical OncologyReimbursement MechanismsBiosimilar PharmaceuticalsCost SavingsDrug SubstitutionHumansUnited StatesBiosimilar Pharmaceuticals

Identifiers

PMID34677089
PMCPMC10394213
OpenAlexW3206821735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.